Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.61 |
| ▸ | HPGD | P15428 | 5/20 | 0.61 |
| ▸ | USP2 | O75604 | 3/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | TSHR | P16473 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | CA2 | P00918 | 1/20 | 0.61 |
| ▸ | BLM | P54132 | 1/20 | 0.61 |
| ▸ | SLC12A2 | P55011 | 1/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.46 |
| ▸ | AQP1 | P29972 | 1/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19300124 | 0.92 | HPGD (0.61) | ALDH1A1HPGDUSP2HSD17B10LMNA | |
| SCHEMBL2741873 | 0.85 | CA2 (0.68) | ALDH1A1HPGDUSP2HSD17B10LMNA | |
| SCHEMBL2741867 | 0.84 | KDM4E (0.72) | ALDH1A1HPGDUSP2HSD17B10LMNA | |
| SCHEMBL18993636 | 0.83 | ALDH1A1 (0.60) | ALDH1A1HPGDUSP2HSD17B10LMNA | |
| Bumetanide SCHEMBL4018308 | 0.83 | CA2 (0.67) | ALDH1A1HPGDUSP2HSD17B10LMNA | |
| SCHEMBL2741865 | 0.82 | KDM4E (0.71) | ALDH1A1HPGDUSP2HSD17B10LMNA | |
| SCHEMBL19300066 | 0.82 | HPGD (0.61) | ALDH1A1HPGDUSP2HSD17B10LMNA | |
| SCHEMBL2875002 | 0.82 | KDM4E (0.69) | ALDH1A1HPGDUSP2HSD17B10LMNA | |
| SCHEMBL2741864 | 0.82 | ALDH1A1 (0.69) | ALDH1A1HPGDUSP2HSD17B10LMNA | |
| SCHEMBL18993714 | 0.80 | KDM4E (0.71) | ALDH1A1HPGDUSP2HSD17B10LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170246131-A1 | BUMETANIDE ANALOGS, COMPOSITIONS, AND METHODS OF USE | NEUROPRO THERAPEUTICS INC (US) | 2017-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170246131-A1 | BUMETANIDE ANALOGS, COMPOSITIONS, AND METHODS OF USE | SLC6A1, SLC6A13, SLC6A11 | ALDH1A1 889/4885HPGD 1373/4885USP2 3353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.